NL1025116A1 - Nieuwe farmaca. - Google Patents

Nieuwe farmaca.

Info

Publication number
NL1025116A1
NL1025116A1 NL1025116A NL1025116A NL1025116A1 NL 1025116 A1 NL1025116 A1 NL 1025116A1 NL 1025116 A NL1025116 A NL 1025116A NL 1025116 A NL1025116 A NL 1025116A NL 1025116 A1 NL1025116 A1 NL 1025116A1
Authority
NL
Netherlands
Prior art keywords
new pharmaceuticals
pharmaceuticals
new
Prior art date
Application number
NL1025116A
Other languages
English (en)
Other versions
NL1025116C2 (nl
Inventor
Kevin Neil Dack
Dafydd Rhys Owen
Christine Anne Louise Watson
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of NL1025116A1 publication Critical patent/NL1025116A1/nl
Application granted granted Critical
Publication of NL1025116C2 publication Critical patent/NL1025116C2/nl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D231/00Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10Drugs for genital or sexual disorders; Contraceptives for impotence
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/061,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D271/00Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/101,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
NL1025116A 2002-12-23 2003-12-23 Nieuwe farmaca. NL1025116C2 (nl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0230025.9A GB0230025D0 (en) 2002-12-23 2002-12-23 Novel pharmaceuticals
GB0230025 2002-12-23

Publications (2)

Publication Number Publication Date
NL1025116A1 true NL1025116A1 (nl) 2004-06-24
NL1025116C2 NL1025116C2 (nl) 2004-10-18

Family

ID=9950328

Family Applications (1)

Application Number Title Priority Date Filing Date
NL1025116A NL1025116C2 (nl) 2002-12-23 2003-12-23 Nieuwe farmaca.

Country Status (15)

Country Link
US (1) US20040138274A1 (nl)
EP (1) EP1578735A1 (nl)
JP (1) JP2006515297A (nl)
AR (1) AR042647A1 (nl)
AU (1) AU2003285641A1 (nl)
BR (1) BR0317644A (nl)
CA (1) CA2511360A1 (nl)
GB (1) GB0230025D0 (nl)
GT (1) GT200300291A (nl)
NL (1) NL1025116C2 (nl)
PA (1) PA8593601A1 (nl)
PE (1) PE20050122A1 (nl)
TW (1) TW200420548A (nl)
UY (1) UY28145A1 (nl)
WO (1) WO2004056787A1 (nl)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1756074A4 (en) * 2004-05-04 2010-05-19 Merck Sharp & Dohme 1,2,4-OXADIAZOLE DERIVATIVES AS INHIBITORS OF DIPEPTIDYLPEPTIDASE-IV IN THE TREATMENT OR PREVENTION OF DIABETES
WO2005123702A1 (en) * 2004-06-15 2005-12-29 Pfizer Limited Neutral endopeptidase inhibitor polymorph
CA2616366A1 (en) 2005-07-29 2007-02-08 Concert Pharmaceuticals Inc. Novel pharmaceutical compounds
AR057882A1 (es) 2005-11-09 2007-12-26 Novartis Ag Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
US20090005381A1 (en) * 2007-06-26 2009-01-01 Philip Manton Brown Methods of treating serotonin-mediated diseases and disorders
PT3083564T (pt) * 2013-12-20 2018-11-07 Novartis Ag Derivados de ácido heteroarilbutanoico como inibidores de lta4h

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8820844D0 (en) * 1988-09-05 1988-10-05 Pfizer Ltd Therapeutic agents
HUP0303624A3 (en) * 2001-03-28 2005-06-28 Pfizer N-phenpropylcyclopentyl-substituted glutaramide derivatives as nep inhibitors for fsad and process for preparation of the compounds

Also Published As

Publication number Publication date
AU2003285641A1 (en) 2004-07-14
PA8593601A1 (es) 2005-05-24
JP2006515297A (ja) 2006-05-25
GB0230025D0 (en) 2003-01-29
PE20050122A1 (es) 2005-01-24
AR042647A1 (es) 2005-06-29
NL1025116C2 (nl) 2004-10-18
US20040138274A1 (en) 2004-07-15
TW200420548A (en) 2004-10-16
CA2511360A1 (en) 2004-07-08
BR0317644A (pt) 2005-12-06
UY28145A1 (es) 2004-07-30
WO2004056787A1 (en) 2004-07-08
GT200300291A (es) 2004-08-13
EP1578735A1 (en) 2005-09-28

Similar Documents

Publication Publication Date Title
NL1026074A1 (nl) Nieuwe Farmaceutica.
NL1027568A1 (nl) Nieuwe farmaceutica.
NO20053248D0 (no) Kerosenblanding.
NO20052991D0 (no) Kinazolinforbindelser.
NL1026438A1 (nl) Nieuwe verbindingen.
NO20052248D0 (no) Svivelstykkesystem.
NO20051500D0 (no) Substituerte heterocyklylpyrimidiner.
DE60305332D1 (de) IMIDAZOi1,2-AöPYRIDINE
ITTO20030507A1 (it) Premistoppa a tenuta di fango.
NO20051497D0 (no) Beta-laktamaseinhibitorprodrug.
ITMI20032170A1 (it) Tagliacimosse.
NL1025116A1 (nl) Nieuwe farmaca.
ITMI20030916A1 (it) Lancetta.
ES1052590Y (es) Quiosco-consigna.
NL1024812A1 (nl) Lampenkap.
ES1052938Y (es) Cantonera.
ES1051605Y (es) Cromo-puzzle.
ES1051110Y (es) Caja-palet.
ES1051703Y (es) Potera.
ES1052654Y (es) Cubitera.
ES1052029Y (es) Balin-proyectil.
ES1052945Y (es) Contraventana.
ES1052011Y (es) Espetero.
ITRE20020089A1 (it) Apparecchiatutto.
ITTO20020722A1 (it) Alchinilcarbossi-nucleotidi.

Legal Events

Date Code Title Description
AD1B A search report has been drawn up
PD2B A search report has been drawn up
VD1 Lapsed due to non-payment of the annual fee

Effective date: 20080701